Zablocki, J.A. et al. , “Fibrinogen Receptor Antagonists”, Expert Opinion on Investigational Drugs, 3:437-448 (1994). |
Choi, E.T., et al., “Inhibition of Neointimal Hyperplasia by Blocking αvβ3 Integrin with a Small Peptide Antagonist GpenGRGDSPCA”, J. Vasc. Surg. 19:125-134 (1994). |
Cook, N.S., et al., “Platelet Glycoprotein IIb/IIIa Antagonists”, Drugs of the Future 19:135-159 (1994). |
T. Weller., et al., “Fibrinogen Receptor Antagonists—A Novel Class of Promising Antithrombotics”, Drugs of the Future 19:461 (1994). |
Hynes, R.O., “Integrins: Versatility, Modulation and Signaling in Cell Adhesion”, Cell 69:11 (1992). |
Yue, T.L., et al., “Osteopontin-Stimulated Vascular Smooth Muscle Cell Migration is Mediated by β3 Integrin”, Exp. Cell. Res. 214:459-464 (1994). |
Matsuno, H., “Inhibition of Integrin Function by A Cyclic RGD-Containing Peptide Prvents Neointima Formation”, Circulation 90:2203-2206 (1994). |
Rouslahti, E. and Pierschbacher, M.D., “New Perspectives in Cell Adhesion: RGD and Integrins”, Science 238:491-497 (1987). |
Coller, B.S., “Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy”, Circulation 92:2373-2380 (1995). |
Pfaff, M., et al., “Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by αIIββ3, αvβ3, and α5β1 Integrins”, J. Biol. Chem. 269:20233-20238 (1994). |